vs
Side-by-side financial comparison of PUMA BIOTECHNOLOGY, INC. (PBYI) and UNIVEST FINANCIAL Corp (UVSP). Click either name above to swap in a different company.
UNIVEST FINANCIAL Corp is the larger business by last-quarter revenue ($87.5M vs $75.5M, roughly 1.2× PUMA BIOTECHNOLOGY, INC.). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 10.2%).
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
Univest Financial Corp is a U.S. regional financial services holding company based in Pennsylvania. It offers banking, wealth management, insurance, and lending solutions for individual consumers, SMEs, and institutional clients across its Mid-Atlantic operating regions.
PBYI vs UVSP — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $75.5M | $87.5M |
| Net Profit | — | $27.1M |
| Gross Margin | 69.3% | — |
| Operating Margin | 22.7% | — |
| Net Margin | — | 31.0% |
| Revenue YoY | 27.7% | — |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.26 | $0.96 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $87.5M | ||
| Q4 25 | $75.5M | $84.6M | ||
| Q3 25 | $54.5M | $83.2M | ||
| Q2 25 | $52.4M | $81.0M | ||
| Q1 25 | $46.0M | $79.2M | ||
| Q4 24 | $59.1M | $76.8M | ||
| Q3 24 | $80.5M | $73.4M | ||
| Q2 24 | $47.1M | $72.0M |
| Q1 26 | — | $27.1M | ||
| Q4 25 | — | $22.7M | ||
| Q3 25 | $8.8M | $25.6M | ||
| Q2 25 | $5.9M | $20.0M | ||
| Q1 25 | $3.0M | $22.4M | ||
| Q4 24 | — | $18.9M | ||
| Q3 24 | $20.3M | $18.6M | ||
| Q2 24 | $-4.5M | $18.1M |
| Q1 26 | — | — | ||
| Q4 25 | 69.3% | — | ||
| Q3 25 | 77.7% | — | ||
| Q2 25 | 76.5% | — | ||
| Q1 25 | 77.1% | — | ||
| Q4 24 | 76.4% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 77.4% | — |
| Q1 26 | — | — | ||
| Q4 25 | 22.7% | 34.0% | ||
| Q3 25 | 17.6% | 38.5% | ||
| Q2 25 | 12.7% | 30.9% | ||
| Q1 25 | 8.7% | 34.8% | ||
| Q4 24 | 22.6% | 30.9% | ||
| Q3 24 | 27.4% | 31.9% | ||
| Q2 24 | -4.6% | 31.4% |
| Q1 26 | — | 31.0% | ||
| Q4 25 | — | 26.9% | ||
| Q3 25 | 16.2% | 30.8% | ||
| Q2 25 | 11.2% | 24.7% | ||
| Q1 25 | 6.5% | 28.3% | ||
| Q4 24 | — | 24.7% | ||
| Q3 24 | 25.2% | 25.3% | ||
| Q2 24 | -9.6% | 25.1% |
| Q1 26 | — | $0.96 | ||
| Q4 25 | $0.26 | $0.78 | ||
| Q3 25 | $0.17 | $0.89 | ||
| Q2 25 | $0.12 | $0.69 | ||
| Q1 25 | $0.06 | $0.77 | ||
| Q4 24 | $0.40 | $0.64 | ||
| Q3 24 | $0.41 | $0.63 | ||
| Q2 24 | $-0.09 | $0.62 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $97.5M | $222.4M |
| Total DebtLower is stronger | $22.7M | $201.2M |
| Stockholders' EquityBook value | $130.3M | $952.0M |
| Total Assets | $216.3M | $8.1B |
| Debt / EquityLower = less leverage | 0.17× | 0.21× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $222.4M | ||
| Q4 25 | $97.5M | — | ||
| Q3 25 | $94.4M | — | ||
| Q2 25 | $96.0M | — | ||
| Q1 25 | $93.2M | — | ||
| Q4 24 | $101.0M | — | ||
| Q3 24 | $96.7M | — | ||
| Q2 24 | $96.8M | — |
| Q1 26 | — | $201.2M | ||
| Q4 25 | $22.7M | — | ||
| Q3 25 | $34.0M | — | ||
| Q2 25 | $45.3M | — | ||
| Q1 25 | $56.7M | — | ||
| Q4 24 | $68.0M | — | ||
| Q3 24 | $79.3M | — | ||
| Q2 24 | $90.7M | — |
| Q1 26 | — | $952.0M | ||
| Q4 25 | $130.3M | $943.3M | ||
| Q3 25 | $115.3M | $933.2M | ||
| Q2 25 | $104.7M | $916.7M | ||
| Q1 25 | $97.1M | $903.5M | ||
| Q4 24 | $92.1M | $887.3M | ||
| Q3 24 | $71.1M | $877.1M | ||
| Q2 24 | $48.5M | $854.1M |
| Q1 26 | — | $8.1B | ||
| Q4 25 | $216.3M | $8.4B | ||
| Q3 25 | $202.9M | $8.6B | ||
| Q2 25 | $194.9M | $7.9B | ||
| Q1 25 | $196.2M | $8.0B | ||
| Q4 24 | $213.3M | $8.1B | ||
| Q3 24 | $220.7M | $8.2B | ||
| Q2 24 | $205.0M | $7.9B |
| Q1 26 | — | 0.21× | ||
| Q4 25 | 0.17× | — | ||
| Q3 25 | 0.30× | — | ||
| Q2 25 | 0.43× | — | ||
| Q1 25 | 0.58× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 1.12× | — | ||
| Q2 24 | 1.87× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $14.4M | — |
| Free Cash FlowOCF − Capex | $14.4M | — |
| FCF MarginFCF / Revenue | 19.1% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $41.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $14.4M | $101.5M | ||
| Q3 25 | $9.7M | $32.0M | ||
| Q2 25 | $14.1M | $23.3M | ||
| Q1 25 | $3.6M | $15.6M | ||
| Q4 24 | $15.6M | $75.1M | ||
| Q3 24 | $11.0M | $38.9M | ||
| Q2 24 | $1.0M | $-3.4M |
| Q1 26 | — | — | ||
| Q4 25 | $14.4M | $96.9M | ||
| Q3 25 | $9.7M | $31.4M | ||
| Q2 25 | $14.1M | $21.9M | ||
| Q1 25 | $3.6M | $13.7M | ||
| Q4 24 | $15.6M | $72.0M | ||
| Q3 24 | $11.0M | $38.3M | ||
| Q2 24 | $1.0M | $-4.2M |
| Q1 26 | — | — | ||
| Q4 25 | 19.1% | 114.6% | ||
| Q3 25 | 17.7% | 37.7% | ||
| Q2 25 | 26.8% | 27.0% | ||
| Q1 25 | 7.7% | 17.2% | ||
| Q4 24 | 26.4% | 93.8% | ||
| Q3 24 | 13.7% | 52.2% | ||
| Q2 24 | 2.1% | -5.9% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 5.4% | ||
| Q3 25 | 0.0% | 0.7% | ||
| Q2 25 | 0.0% | 1.7% | ||
| Q1 25 | 0.1% | 2.5% | ||
| Q4 24 | 0.0% | 4.0% | ||
| Q3 24 | 0.0% | 0.8% | ||
| Q2 24 | 0.0% | 1.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | 4.46× | ||
| Q3 25 | 1.10× | 1.25× | ||
| Q2 25 | 2.41× | 1.16× | ||
| Q1 25 | 1.21× | 0.70× | ||
| Q4 24 | — | 3.97× | ||
| Q3 24 | 0.54× | 2.09× | ||
| Q2 24 | — | -0.19× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PBYI
Segment breakdown not available.
UVSP
| Net Interest Income | $63.4M | 72% |
| Noninterest Income | $24.1M | 28% |
